Trial Profile
99mTc-rhAnnexin V-128 Imaging of Apoptosis and Cardiotoxicity in Relationship to Ventricular Function in Patients With Early Stage Breast Cancer Receiving Doxorubicin-Based Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tc-99m annexin V 128 (Primary)
- Indications Cardiomyopathies
- Focus Diagnostic use; Proof of concept
- Sponsors Advanced Accelerator Applications
- 11 Mar 2019 Status changed from recruiting to discontinued.
- 16 Aug 2018 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.
- 16 Aug 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.